Rocket Pharmaceuticals, Inc. (GETTEX:9IP1) Financings
Financings
| Raise | Date |
|---|---|
| Term loan credit facility with warrants Tranche closed: US$35M raised · warrants to purchase shares of Rocket's common stock · LifeSci Capital +1 Dealers: LifeSci Capital, PJT Buyers: Hercules Capital, Inc. (credit facility for up to $150 million; $35 million funded at closing) Use of proceeds: Support the pivotal Phase 2 study of RP-A501 for Danon disease and advance the broader cardiovascular pipeline | Oct 6, 2026 |
| Public offering of shares of common stock Made bigger: US$165M · US$12.5 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital | Dec 11, 2024 |